Home
NewsNewsThe Relocation of Westminster Fertility Clinic to Long Beach by RPMG will expand access and improve specialized services for the Southern California region.
Reproductive Partners Medical Group - RPMG, a nationally respected leader in fertility care and family building, is part of the nationally recognized fertility care network, Ivy Fertility, has announced the relocation of Westminster fertility clinic to a newly designed and patient-focused facility that is complete with a lab as well as a surgery center based in California’s Long Beach.
The move is made to better serve patients based across greater Los Angeles as well as Orange County with enhanced access, care, and continuity and also an upgraded clinic experience that is grounded in scientific excellence along with individualized support. It is well to be noted that for over three decades, RPMG has in fact stood right at the forefront of fertility medicine, enabling individuals and also couples having diverse backgrounds to attain their dreams of parenthood by way of comprehensive services such as IVF, IUI, genetic testing, fertility preservation, and LGBTQ+ family building, as well as advanced reproductive care.
This kind of move goes on to represent more than just a change of address. It is indeed a step forward in how one goes on to deliver care with empathy along with clinical excellence at every stage, remarked the board-certified reproductive endocrinologist with Reproductive Partners Medical Group, Marli Amin, MD. Dr. Amin goes on to bring her expertise within IVF, egg freezing, IUI along with comprehensive fertility testing and also customized patient guidance, to the heart of this new location.
Besides setting up this gorgeous new clinic infused with a lab as well as a surgery center by relocating the Westminster fertility clinic, the Long Beach clinic is also going to provide the same trusted as well as evidence-based treatment plans, and along with it, continuity of care, which the patients have come to depend on, delivered by the world-class team of fertility experts along with the clinical support staff of RPMG.
The fact is that moving to Long Beach highlights their dedication to widening their access without compromising on the customized attention that their patients expect, said the Chief Operating Officer of Reproductive Partners Medical Group, Christina Westbrook. The present patients are going to continue receiving uninterrupted care, and the new patients are invited to have scheduled consultations at the Long Beach setup. The operational hours and contact information, along with support services, remain synced with the commitment to responsive and patient-centered service of RPMG.
Legacy, North America's leading digital male fertility clinic, has secured New York State CLEP approval for both its semen analysis and DNA fragmentation test – the only mandatory pre-market laboratory review programme in the United States. The approvals confirm clinical-grade validity for at-home samples, extending access to New York patients without a clinic visit.
From 1 July 2026, South Australia's Fertility Treatment Rebate Scheme provides eligible residents with a $250 rebate for pre-treatment testing and a $2,000 rebate for up to two fertility treatment cycles. Backed by an $18.5 million, four-year government commitment, the scheme directly addresses the financial barriers preventing South Australians from accessing fertility care.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
